WINNING THE BATTLE AGAINST ENDOTOXIC SEPTIC SHOCK

The first theranostic: EAA™ & Toraymyxin™

Learn More

Media

Spectral combining diagnostics with targeted therapy in novel approach to septic shock.

BioTuesdays, November 12, 2024

READ MORE...

Spectral team's sepsis awareness day event

Endotoxic Septic Shock & Precision Medicine

Sepsis is a life-threatening condition caused by the body’s overwhelming response to bacterial components like endotoxin. It remains a major global health challenge, affecting millions each year. If not recognized and treated quickly, sepsis can lead to multiple organ failure, shock, and even death. Importantly, endotoxic septic shock (ESS) is the most malignant form of sepsis with a mortality rate in excess of 50%.

At Spectral Medical Inc., we are committed to fighting endotoxic septic shock with our unique theranostic approach. This strategy combines two critical components: the EAA™ Endotoxin Activity Assay, which enables rapid detection of endotoxin activity, and Toraymyxin™ PMX extracorporeal hemoadsorption therapy, designed to remove endotoxins directly from the bloodstream.

 

Spectral team's sepsis awareness day event

Precision Medicine in Action: The Tigris Trial

Our targeted approach to endotoxic septic shock is demonstrated through the Tigris trial, a pivotal clinical study evaluating PMX therapy for patients with ESS. Our recently announced topline results showed that PMX met its prespecified primary endpoint for 28-day mortality, with a posterior probability of benefit of 95.3%. Observed 28-day mortality in the intention-to-treat cohort was 38.7% with PMX versus 45.1% with standard of care, an absolute difference of 6.4%. The severity-adjusted posterior odds ratio was 0.67 [0.39-1.08] using the Bayesian analysis.

The key secondary endpoint, 90-day mortality, demonstrated even more substantial benefit, with a posterior probability of benefit exceeding 99%, an adjusted odds ratio of 0.54 [0.32-0.87], and a number needed to treat (NNT) of 8.1 to save one life at 90 days. These results highlight the potential of Targeted Rapid Endotoxin Adsorption (TREA) to guide precision, data-driven therapy in the ICU. By identifying patients most likely to benefit, clinicians can deliver interventions that directly address the underlying cause of septic shock, moving beyond generalized treatment protocols. Read the full press release here.

Unite for Sepsis Symposium

Spectral was proud to sponsor the Unite for Sepsis Symposium, held September 8–9 in Chicago.

This groundbreaking event brought together an extraordinary community of clinicians, researchers, innovators, regulators, and advocates, united in a shared mission to transform how we prevent, diagnose, and treat sepsis.

Unite for Sepsis proved to be more than a symposium; it was a movement toward collaboration, innovation, and action to save lives and improve patient outcomes worldwide.

Personalizing Sepsis Treatment

We were proud to have Debra Foster, Clinical Consultant at Spectral Medical, participate in the Unite for Sepsis Symposium held September 8–9 in Chicago.

Debra contributed to the session “Personalizing Sepsis Treatment” on Day 1, sharing insights on how individualized approaches can enable earlier intervention and improve outcomes in sepsis care.

Her participation was part of a broader effort that brought together clinicians, researchers, innovators, and policymakers—uniting expertise and vision to advance the prevention, diagnosis, and treatment of sepsis.

Latest News
Investor Updates

August 2025 Investor Update

Tigris Trial Topline Results Call Replay

August 13, 2025

Events

Critical Care Canada Forum

CCCF 2025 Keynote Session

TIGRIS: A Clinical Trial for Septic Shock With Endotoxemia
Speakers: Dr. Matthieu Legrand & Dr. John Kellum
Editorial Commentary: Dr. Marlies Ostermann
Moderators: Dr. Christopher Seymour & Dr. John Marshall

Monday, December 1, 2025 @5:00–6:00 PM EST
Toronto Sheraton Hotel Grand Ballroom East | Hybrid Session

43rd Vicenza Course

AKI–CRRT–EBPT and Critical Care Nephrology

Session: Sepsis and Sepsis-Associated AKI
Presentation: Endotoxin in Sepsis-Associated AKI: Tigris Update
presented by John Kellum, MD, MCCM

Wednesday, June 25th at 11:00
Room Tiziano A, Vicenza Convention Centre

43rd Vicenza Course

AKI–CRRT–EBPT and Critical Care Nephrology

Session: Extracorporeal Therapeutic Options in ICU
Presentation: Managing Endotoxemia with Hemoadsorption
presented by John Kellum, MD, MCCM

Wednesday, June 25th at 16:00
Room Tiziano A, Vicenza Convention Centre

REPLAYS
I

Endotoxin, The Phantom Menace of Sepsis

Sepsis Alliance Institute Sponsor Innovation Webinar:
Debra Foster, BSc
Mark A. Tidswell, MD, Professor of Medicine,
UMASS Chan Medical School – Baystate
Thursday October 3, 2024 @ 11am PT | 2pm ET

What part does endotoxin play in the etiology of sepsis and septic shock? This sponsored webinar will describe the human response to elevated levels of endotoxin, both as an adaptive immune response and also as a trigger of sepsis. The ability to measure endotoxin activity in the bloodstream allows clinicians to uncloak its true prevalence and closely examine when endotoxin plays a role in sepsis. Can targeting endotoxin removal be a successful treatment modality for sepsis? Tune in to this webinar to learn more.

Watch the Replay

I

Waking up to Endotoxemic Septic Shock

CRRT Conference Breakfast Symposium
Waking up to Endotoxemic Septic Shock. What do you need to be ready?
Wednesday March 13, 2024
San Diego, CA

Moderators: John Kellum and Debra Foster
Diagnosing ESS in the real world – Danielle Davison, George Washington University
Treating ESS in the real world – Javier Neyra, University of Alabama
Implementing PMX hemoadsorption at the bedside – Johann Chang, (Spectral), Tara Morgan-Gray, (Colorado Springs)

I

Advancing Therapeutic Options for Sepsis and Endotoxic Septic Shock

Featured on The Balancing Act on Lifetime TV.